AsiaOligonucleotide, Peptide
Changzhou, China
API Process Development and Manufacturing for Oligonucleotides, Peptides & Conjugates
Site detail
Asia
Shanghai Waigaoqiao, China
Discovery Synthesis for Oligonucleotide, Peptide & Conjugate Pre-formulation & Formulation Development for Oligonucleotides, Peptides & Conjugates
Please contact us for the full virtual tour.
Discovery Synthesis for Oligonucleotide, Peptide & Conjugate Pre-formulation & Formulation Development for Oligonucleotides, Peptides & Conjugates
- 90 Delin Road Waigaoqiao Free Trade Zone, Shanghai, 200131, China
The site offers oligonucleotide and peptide discovery synthesis from library screening to preclinical candidates’ selection. It also provides pre-formulation and formulation development for both oral and injectable dosage forms. The analytical teams support drug product from preclinical to commercial manufacturing. Additionally, the team offers lipid nanoparticle formulation development for TIDES drugs.
Our Waigaoqiao site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, and South Korea MFDS.
Site Virtual Tour
Site Related News
Three Sites from WuXi STA Receive Top EcoVadis Scores for Business Sustainability Rating
WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for act...
WuXi STA Successfully Passes Four Pre-Approval Inspections by South Korea’s Ministry of Food and Drug Safety at Three Manufacturing Sites in China
SHANGHAI, CHINA, October 12, 2022 – WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announc...
Three WuXi STA Facilities Pass Pre-Approval Inspection From NMPA
SHANGHAI, CHINA, April, 12, 2021 – STA Pharmaceutical, a WuXi AppTec company (WuXi STA), a leading contract development and manufacturing organizati...
WuXi STA Opens a New Clinical Supply Service Facility at Shanghai Waigaoqiao Site
New service further accelerates drug candidates to clinical trials through CRDMO platform
Shanghai, China, September 30, 2022 - WuXi STA, a WuXi AppT...
Three Sites from WuXi STA Receive Top EcoVadis Scores for Business Sustainability Rating
WuXi STA, a subsidiary of WuXi AppTec, received the latest scores from EcoVadis rating, a trusted provider of business sustainability ratings, for act...
WuXi STA Successfully Passes Four Pre-Approval Inspections by South Korea’s Ministry of Food and Drug Safety at Three Manufacturing Sites in China
SHANGHAI, CHINA, October 12, 2022 – WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announc...
Three WuXi STA Facilities Pass Pre-Approval Inspection From NMPA
SHANGHAI, CHINA, April, 12, 2021 – STA Pharmaceutical, a WuXi AppTec company (WuXi STA), a leading contract development and manufacturing organizati...
WuXi STA Opens a New Clinical Supply Service Facility at Shanghai Waigaoqiao Site
New service further accelerates drug candidates to clinical trials through CRDMO platform
Shanghai, China, September 30, 2022 - WuXi STA, a WuXi AppT...
Nearby in the network
Other sites
How can we help?
Our TIDES drug experts stand ready.
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA